Varex Imaging Corporation has announced its unaudited financial results for the second quarter of fiscal year 2025, reporting revenues of $213 million, reflecting a 3% increase compared to the same period in the previous year. The medical segment contributed $154 million to the revenue, while the industrial segment accounted for $59 million, both showing a 3% year-over-year growth. The GAAP gross margin stood at 36%, with a GAAP operating margin of 10% and a non-GAAP operating margin of 12%. Net earnings were reported at $0.17 per diluted share, with non-GAAP net earnings at $0.26 per diluted share, an increase from $0.16 in the same quarter of fiscal year 2024. Cash flow from operations reached $17 million in the second quarter. The company ended the quarter with cash, cash equivalents, and marketable securities totaling $226 million, excluding $125 million of restricted cash related to the Senior Secured Note Add On. Despite the positive results, Varex indicated a short-term reduction in outlook due to high tariffs imposed by China on U.S. products, leading to paused purchases from several China-based customers.